Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 10/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886881 | 1.00 | GRIA2 (0.41) | GRIA2CDK1CDK9CDK2ALOX5AP | |
| SCHEMBL2881889 | 1.00 | GRIA2 (0.41) | GRIA2CDK1CDK9CDK2ALOX5AP | |
| SCHEMBL2884473 | 0.76 | USP30 (0.35) | ALOX5APFEN1BRAF | |
| SCHEMBL2884471 | 0.76 | USP30 (0.35) | ALOX5APFEN1BRAF | |
| SCHEMBL91038 | 0.68 | GRIA2 (0.47) | GRIA2CYP2C19 | |
| SCHEMBL90957 | 0.66 | MKNK1 (0.57) | GRIA2CYP2C19 | |
| SCHEMBL90961 | 0.64 | GRIA2 (0.42) | GRIA2CDK9CYP2C19GRIA4 | |
| SCHEMBL91002 | 0.64 | GRIA2 (0.48) | GRIA2CYP2C19 | |
| SCHEMBL90865 | 0.64 | GRIA2 (0.47) | GRIA2CDK2CYP2C19GRIA4 | |
| SCHEMBL13439180 | 0.64 | CNR1 (0.49) | GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | claimed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | GRIA2 585/4885CDK1 976/4885CDK9 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.